Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hasna Hassikou

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Rheumatology International|January 2, 2021
One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registrySafaa Fellous, Hanan Rkain, Samir Ahid, et al.
The Pan African Medical Journal|May 17, 2021
The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapiesMeryem Eddaoudi, Samira Rostom, Ihsane Hmamouchi, et al.
Mediterranean Journal of Rheumatology|June 25, 2025
Tuberculosis Under Biotherapy in Patients with Spondyloarthritis: Data from the Moroccan Biotherapy Registry (RBSMR) during 3 Years of Follow UpSalma Zemrani, Bouchra Amine, Imane Elbinoune, et al.
Mediterranean Journal of Rheumatology|September 21, 2022
Therapeutic Maintenance Level of Methotrexate in Rheumatoid Arthritis: A RBSMR StudyLamia Oulkadi, Samira Rostom, Ihsane Hmamouchi, et al.
Rheumatology International|June 26, 2021
Prevalence of latent tuberculosis before biotherapy initiation in rheumatoid arthritis and spondyloarthritis: data from the Moroccan biotherapy registryLamia Oulkadi, Samira Rostom, Ihsane Hmamouchi, et al.
Current Rheumatology Reviews|January 22, 2026
Factors Determining the Switch of the First Biological Treatment in Spondyloarthritis: Data from the RBSMR RegistryOumaima Idrissi Ouali, Imane El Mezouar, Nessrine Akasbi, et al.
Mediterranean Journal of Rheumatology|January 31, 2025
Tumour Necrosis Factor α Inhibitors during Spondylarthritis: Therapeutic Maintenance, Reasons, and Predictive Factors of Discontinuation (Data from RBSMR Registry)Oumaima Idrissi Ouali, Salma Mikou, Imane El Mezouar, et al.
Mediterranean Journal of Rheumatology|December 19, 2022
Extra-Articular Manifestations in Patients with Ankylosing Spondylitis: Baseline Characteristics from the RBSMR StudyNajlae El Ouardi, Julien H Djossou, Laila Taoubane, et al.
International Journal of Mycobacteriology|July 1, 2022
Active tuberculosis infection in moroccan patients with rheumatic diseases under biologic therapy: A multicenter national studyIlham Aachari, Latifa Tahiri, Gehan Elolemy, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Rheumatology International|January 2, 2021
One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registrySafaa Fellous, Hanan Rkain, Samir Ahid, et al.
The Pan African Medical Journal|May 17, 2021
The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapiesMeryem Eddaoudi, Samira Rostom, Ihsane Hmamouchi, et al.
Mediterranean Journal of Rheumatology|June 25, 2025
Tuberculosis Under Biotherapy in Patients with Spondyloarthritis: Data from the Moroccan Biotherapy Registry (RBSMR) during 3 Years of Follow UpSalma Zemrani, Bouchra Amine, Imane Elbinoune, et al.
Mediterranean Journal of Rheumatology|September 21, 2022
Therapeutic Maintenance Level of Methotrexate in Rheumatoid Arthritis: A RBSMR StudyLamia Oulkadi, Samira Rostom, Ihsane Hmamouchi, et al.
Rheumatology International|June 26, 2021
Prevalence of latent tuberculosis before biotherapy initiation in rheumatoid arthritis and spondyloarthritis: data from the Moroccan biotherapy registryLamia Oulkadi, Samira Rostom, Ihsane Hmamouchi, et al.
Current Rheumatology Reviews|January 22, 2026
Factors Determining the Switch of the First Biological Treatment in Spondyloarthritis: Data from the RBSMR RegistryOumaima Idrissi Ouali, Imane El Mezouar, Nessrine Akasbi, et al.
Mediterranean Journal of Rheumatology|January 31, 2025
Tumour Necrosis Factor α Inhibitors during Spondylarthritis: Therapeutic Maintenance, Reasons, and Predictive Factors of Discontinuation (Data from RBSMR Registry)Oumaima Idrissi Ouali, Salma Mikou, Imane El Mezouar, et al.
Mediterranean Journal of Rheumatology|December 19, 2022
Extra-Articular Manifestations in Patients with Ankylosing Spondylitis: Baseline Characteristics from the RBSMR StudyNajlae El Ouardi, Julien H Djossou, Laila Taoubane, et al.
International Journal of Mycobacteriology|July 1, 2022
Active tuberculosis infection in moroccan patients with rheumatic diseases under biologic therapy: A multicenter national studyIlham Aachari, Latifa Tahiri, Gehan Elolemy, et al.
Pageof 2